deferasirox has been researched along with Experimental Hepatoma in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Fujisawa, K; Hidaka, I; Ishikawa, T; Iwamoto, T; Maeda, M; Matsumoto, T; Saeki, I; Sakaida, I; Takami, T; Tani, K; Uchida, K; Yamamoto, N; Yamasaki, T | 1 |
Aihara, Y; Fukui, H; Ikenaka, Y; Kaji, K; Kawaratani, H; Kitade, M; Namisaki, T; Noguchi, R; Shirai, Y; Tsujimoto, T; Yanase, K; Yoshii, J; Yoshiji, H | 1 |
Brissot, P; Chantrel-Groussard, K; Gaboriau, F; Lescoat, G; Nick, H; Pasdeloup, N | 1 |
1 trial(s) available for deferasirox and Experimental Hepatoma
Article | Year |
---|---|
Effects of an oral iron chelator, deferasirox, on advanced hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Animals; Benzoates; Carcinoma, Hepatocellular; Deferasirox; Drug Screening Assays, Antitumor; Female; Hep G2 Cells; Humans; Iron Chelating Agents; Liver Neoplasms, Experimental; Male; Mice; Mice, Inbred C57BL; Middle Aged; Triazoles | 2016 |
2 other study(ies) available for deferasirox and Experimental Hepatoma
Article | Year |
---|---|
Combination treatment of angiotensin II type I receptor blocker and new oral iron chelator attenuates progression of nonalcoholic steatohepatitis in rats.
Topics: Administration, Oral; Angiogenesis Inhibitors; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Benzoates; Carcinoma, Hepatocellular; Cell Proliferation; Cells, Cultured; Choline Deficiency; Deferasirox; Disease Progression; Drug Therapy, Combination; Fatty Liver; Hepatic Stellate Cells; Iron Chelating Agents; Liver Cirrhosis, Experimental; Liver Neoplasms, Experimental; Losartan; Male; Neovascularization, Pathologic; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Rats; Rats, Inbred F344; Time Factors; Transforming Growth Factor beta1; Triazoles | 2011 |
Antiproliferative and apoptotic effects in rat and human hepatoma cell cultures of the orally active iron chelator ICL670 compared to CP20: a possible relationship with polyamine metabolism.
Topics: Animals; Apoptosis; Base Sequence; Benzoates; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemotherapy, Adjuvant; Deferasirox; Deferiprone; DNA Primers; DNA Replication; Humans; Iron Chelating Agents; Liver Neoplasms; Liver Neoplasms, Experimental; Polyamines; Pyridones; Rats; Triazoles | 2007 |